Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Unresectable Hepatocellular Carcinoma: early-phase trial registry
6 of 13 indexed Unresectable Hepatocellular Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,315 of 28,707 conditions by registered trial count.
13 US clinical trials · 6 currently recruiting · #1,315 of 28,707 conditions by registered trial count
Unresectable Hepatocellular Carcinoma: 13 US clinical trials tracked, 6 recruiting.
Unresectable Hepatocellular Carcinoma is the subject of 13 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is Mayo Clinic, running 2 of these trials.
Enrollment posture brief
Registry condition unresectable-hepatocellular-carcinoma
OPEN 6 | RECR 46% | LATE 1 | EARLY 9 | RANK #1315 | SPON 2
Volume-matched condition peers
Nearest open-share peer: B-cell Lymphoma (46% recruiting · 39 trials)
Unresectable Hepatocellular Carcinoma lists 6 open slots (46% of 13 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Unresectable Hepatocellular Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Unresectable Hepatocellular Carcinoma recruits in line with its size-band peers.
6 of 13 indexed trials (46.2%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Unresectable Hepatocellular Carcinoma research.
Mayo Clinic accounts for 2 of 13 trials (15.4%). 12 distinct sponsors appear on at least one study for this condition label.
-
Most Unresectable Hepatocellular Carcinoma trials plan to enrol fewer than 100 people.
Median target enrolment is 42 among the 13 trials that report a genuine target (sentinel values excluded). 9 of those (69.2%) plan for fewer than 100 participants.
-
Unresectable Hepatocellular Carcinoma research is mostly interventional.
12 interventional and 1 observational studies make up this index (92.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
13 total, page 1 of 1
An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery
Bayer
NCT06117891
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
Academic and Community Cancer Research United
NCT05168163
Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer
Mayo Clinic
NCT03942328
Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma
University of Miami
NCT06902246
Atezolizumab+Bevacizumab+SBRT in Unresectable HCC
Massachusetts General Hospital
NCT05096715
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
Emory University
NCT05103904
Radiation Therapy With Protons or Photons in Treating Patients With Liver Cancer
NRG Oncology
NCT03186898
Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients
Sirtex Medical
NCT04736121
A Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma
Howard S Hochster
NCT04829383
Radioembolization for HCC Patients With Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D)
M.D. Anderson Cancer Center
NCT03896646
Delivering a Diuretic Into the Liver Artery Followed by Plugging up the Artery to Starve Out Liver Cancer Cells
Memorial Sloan Kettering Cancer Center
NCT03107416
Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer
City of Hope Medical Center
NCT04605731
68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer
Mayo Clinic
NCT05176223
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 5 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Unresectable Hepatocellular Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Unresectable Hepatocellular Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Unresectable Hepatocellular Carcinoma page
13 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 6 Unresectable Hepatocellular Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Mayo Clinic sponsors the most Unresectable Hepatocellular Carcinoma trials on record, review their full trial history before evaluating a specific study. See Mayo Clinic's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Unresectable Hepatocellular Carcinoma condition card totals 13 registered trials; most-linked intervention Atezolizumab; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.